Inventor · disambiguated record
Xiaohu Fan
Also filed as: FAN XIAOHU
9 granted patents·21 pending applications·35 citations·filing 2016–2024
83Inventor score
Files withNANJING LEGEND BIOTECH CO LTD15LEGEND BIOTECH USA INC6JANSSEN BIOTECH INC4LEGEND BIOTECH IRELAND LTD3JIANGSU KOYOE ENERGY TECH CO LTD1
Top patents by PatentIndex Score
30 records- 0194US10934363B2Chimeric antigen receptors based on single domain antibodies and methods of use thereofLEGEND BIOTECH USA INC·Filed 2016·Granted Mar 2, 2021·24 cites·24 claims
- 0293US11186647B2Chimeric antigen receptors targeting BCMA and methods of use thereofLEGEND BIOTECH USA INC·Filed 2021·Granted Nov 30, 2021·4 cites·21 claims
- 0388US12351638B2Chimeric antigen receptors targeting BCMA and methods of use thereofLEGEND BIOTECH USA INC·Filed 2021·Granted Jul 8, 2025·1 cites·8 claims
- 0485US11535677B2Chimeric antigen receptors targeting BCMA and methods of use thereofLEGEND BIOTECH USA INC·Filed 2017·Granted Dec 27, 2022·3 cites·26 claims
- 0582US2024409654A1Chimeric antigen receptors targeting bcma and methods of use thereofLEGEND BIOTECH USA INC·Filed 2024·Application pending·0 cites
- 0679US12258418B2Claudin18.2 binding moieties and uses thereofNANJING GENSCRIPT BIOTECH CO LTD·Filed 2019·Granted Mar 25, 2025·2 cites·20 claims
- 0774US12231062B1High-voltage three-phase four-bridge-arm topology structure and inverterJIANGSU KOYOE ENERGY TECH CO LTD·Filed 2024·Granted Feb 18, 2025·1 cites·10 claims
- 0859US2021261675A1Chimeric antigen receptors based on single-domain antibodies and methods of use thereofLEGEND BIOTECH USA INC·Filed 2021·Application pending·0 cites
- 0957US2024000836A1Bcma-targeted car-t cell therapy for multiple myelomaJANSSEN BIOTECH INC·Filed 2021·Application pending·0 cites
- 1057US2022265710A1Bcma-targeted car-t cell therapy for multiple myelomaJANSSEN BIOTECH INC·Filed 2021·Application pending·0 cites
- 1157US2023270786A1Bcma-targeted car-t cell therapy for multiple myelomaJANSSEN BIOTECH INC·Filed 2023·Application pending·0 cites
- 1256US2023085615A2Engineered t cells and methods of producing thereofNANJING LEGEND BIOTECH CO LTD·Filed 2020·Application pending·0 cites
- 1356US2022313738A1Nef-containing t cells and methods of producing thereofNANJING LEGEND BIOTECH CO LTD·Filed 2020·Application pending·0 cites
- 1455US2024316201A1Engineered immune effector cells expressing exogenously introduced cytokinesNANJING LEGEND BIOTECH CO LTD·Filed 2022·Application pending·0 cites
- 1555US2024350545A1Modified immune cells expressing tlr receptorsLEGEND BIOTECH IRELAND LTD·Filed 2022·Application pending·0 cites
- 1655US2024209050A1Mutant il-15 compositions and methods thereofLEGEND BIOTECH IRELAND LTD·Filed 2022·Application pending·0 cites
- 1754US11401317B2Human-CD123-targeting chimeric receptor ligand and application thereofNANJING LEGEND BIOTECH CO LTD·Filed 2017·Granted Aug 2, 2022·0 cites·23 claims
- 1854US2024366761A1Fusion proteins and uses thereofLEGEND BIOTECH IRELAND LTD·Filed 2022·Application pending·0 cites
- 1952US2023192883A1Cd19 binding molecules and uses thereofNANJING LEGEND BIOTECH CO LTD·Filed 2021·Application pending·0 cites
- 2052US2023277589A1Bcma-targeted car-t cell therapy for multiple myelomaJANSSEN BIOTECH INC·Filed 2022·Application pending·0 cites
- 2152US2023250184A1Cd22 binding molecules and uses thereofNANJING LEGEND BIOTECH CO LTD·Filed 2021·Application pending·0 cites
- 2249US2023088461A1Antibodies and chimeric antigen receptors targeting glypican-3 (gpc3) and methods of use thereofNANJING LEGEND BIOTECH CO LTD·Filed 2021·Application pending·0 cites
- 2348US2023058669A1Single domain antibodies and chimeric antigen receptors targeting bcma and methods of use thereofNANJING LEGEND BIOTECH CO LTD·Filed 2020·Application pending·0 cites
- 2448US2022177524A1Nef-containing t cells and methods of producing thereofNANJING LEGEND BIOTECH CO LTD·Filed 2019·Application pending·0 cites
- 2547US2023192841A1Claudin18.2 binding moieties and uses thereofNANJING LEGEND BIOTECH CO LTD·Filed 2020·Application pending·0 cites
- 2646US2023257475A1Multispecific chimeric antigen receptors and uses thereofNANJING LEGEND BIOTECH CO LTD·Filed 2021·Application pending·0 cites
- 2745US11564945B2Chimeric antigen receptor and use thereofNANJING LEGEND BIOTECH CO LTD·Filed 2017·Granted Jan 31, 2023·0 cites·22 claims
- 2842US2019038671A1Engineered mammalian cells for cancer therapyNANJING LEGEND BIOTECH CO LTD·Filed 2017·Application pending·0 cites
- 2941US2021363218A1Multispecific chimeric receptors comprising an nkg2d domain and methods of use thereofNANJING LEGEND BIOTECH CO LTD·Filed 2018·Application pending·0 cites
- 3040US11827713B2Chimeric antibody immune effector cell engagers and methods of use thereofNANJING LEGEND BIOTECH CO LTD·Filed 2018·Granted Nov 28, 2023·0 cites·28 claims
Join the waitlist — get patent alerts
Get an alert when Xiaohu Fan files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →